596851 Disclosed is the use of rifaximin in the manufacture of a medicament in maintaining remission of hepatic encephalopathy (HE) in a subject wherein rifaximin is formulated for administration daily to a subject for a period of about 12 months or longer, thereby maintaining remission of HE.